![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Trade Groups Urge FDA to Re-examine Off-Label Standards
Trade Groups Urge FDA to Re-examine Off-Label Standards
![](https://www.fdanews.com/ext/resources/test/Drug-Images3/drug-labeling.jpg?t=1470344596&width=430)
August 4, 2016
Industry trade group giants, PhRMA and BIO are nudging FDA to re-examine how it regulates off-label communication between drugmakers, health-care providers and payers.
PhRMA and BIO jointly published a set of principles covering what they believe drugmakers should and should not be allowed to share with doctors, insurance companies and pharmacy benefit managers. The FDA’s rules governing off-label information exchanges — which are intended to limit off-label promotion — are frequently challenged by industry on First Amendment grounds.
Upcoming Events
-
21Oct